EMG
NBIX icon

Ellington Management Group’s Neurocrine Biosciences NBIX Stock Holding History

Ellington Management Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,100
Closed -$268K – 289
2020
Q1 		$268K Buy
+3,100
New +$303K 0.06% 357
2017
Q3 		– Sell
-17,100
Closed -$787K – 776
2017
Q2 		$787K Buy
17,100
+5,500
+47% +$267K 0.11% 131
2017
Q1 		$502K Buy
+11,600
New +$497K 0.02% 303
2015
Q4 		– Sell
-5,300
Closed -$211K – 732
2015
Q3 		$211K Buy
+5,300
New +$256K 0.06% 559

Other funds holding NBIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return